	US 12,428,626 B2
	Cells for the production of viruses and methods of using the same
Jia Liu, Little Rock, AR (US)
Assigned to BioVentures, LLC, Little Rock, AR (US)
Appl. No. 17/295,761
Filed by BioVentures, LLC, Little Rock, AR (US)
PCT Filed Nov. 20, 2019, PCT No. PCT/US2019/062470 § 371(c)(1), (2) Date May 20, 2021, PCT Pub. No. WO2020/106880, PCT Pub. Date May 28, 2020.
Claims priority of provisional application 62/769,834, filed on Nov. 20, 2018.
Prior Publication US 2022/0010285 A1, Jan. 13, 2022
Int. Cl. C12N 7/00 (2006.01); C12N 9/22 (2006.01); C12N 15/11 (2006.01)

CPC C12N 7/00 (2013.01) [C12N 9/22 (2013.01); C12N 15/111 (2013.01); C12N 2710/24052 (2013.01)]

5 Claims

1. A method of producing a virus comprising introducing a virus into a modified cell, wherein the cell is modified to eliminate or reduce the activity or expression of a Sterile α motif-domain containing protein 9 (SAMD9) polypeptide as compared to a control cell, and wherein the virus is selected from the group consisting of a herpes simplex virus, a rotavirus, a reovirus, an influenza virus, and an adenovirus and wherein the modified cell produces at least a log₁₀increase in virus titer as compared with a control cell.